6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02438215
(ClinicalTrials.gov)
August 20147/8/2014Study of IRX4204 for Treatment of Early Parkinson's DiseaseAn Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease SubjectsParkinson's DiseaseDrug: IRX4204Io TherapeuticsNULLCompleted18 YearsN/ABoth15Phase 1United States
2NCT00387075
(ClinicalTrials.gov)
November 200610/10/2006A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseParkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson DiseaseParkinson DiseaseProcedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CITInstitute for Neurodegenerative DisordersUnited States Department of Defense;Molecular NeuroImagingActive, not recruiting50 YearsN/AAll3000Phase 2United States
3NCT00315250
(ClinicalTrials.gov)
January 200614/4/2006Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseDevelopment of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseParkinson's Disease;Parkinsonian SyndromeDrug: [123I]ß-CITInstitute for Neurodegenerative DisordersDepartment of Defense;Molecular NeuroImagingCompleted22 YearsN/ABoth225Phase 2United States
4NCT00096720
(ClinicalTrials.gov)
February 200412/11/2004Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseInvestigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson'sParkinson Disease;Parkinsonian SyndromeDrug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersBoehringer Ingelheim;Department of DefenseCompleted30 YearsN/ABoth112Phase 2United States
5NCT00134784
(ClinicalTrials.gov)
April 200023/8/2005Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's DiseaseParkinson DiseaseDrug: [123I]B-CIT SPECT imagingInstitute for Neurodegenerative DisordersUnited States Department of DefenseCompleted22 YearsN/AAll142Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00132626
(ClinicalTrials.gov)
September 199218/8/2005Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian SyndromeDynamic SPECT Imaging With [123I]ß-CIT in Patients With ParkinsonismParkinson's Disease;Parkinsonian SyndromeDrug: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersMolecular NeuroImaging;National Institutes of Health (NIH)Completed35 YearsN/AAll500Phase 2NULL